Browsing by Author "Asheesh Shanker"

Now showing 1 - 3 of 3

Correction: Quantum curcumin mediated inhibition of gingipains and mixed-biofilm of Porphyromonas gingivalis causing chronic periodontitis(RSC Advances (2018) 8 (40426–40445) DOI: 10.1039/C8RA08435A)
(Royal Society of Chemistry, 2019) Ashish Kumar Singh; Shivangi Yadav; Kavyanjali Sharma; Zeba Firdaus; Prerana Aditi; Kaushik Neogi; Monika Bansal; Munesh Kumar Gupta; Asheesh Shanker; Rakesh Kumar Singh; Pradyot Prakash
The authors regret the incorrect naming of the bacterial species Actinomycetemcomitans viscosus in the published article. It should be correctly shown as Actinomyces viscosus throughout, on pages 40427 (fifth line of last paragraph), 40436 (sixth line of “Individual isolates & mixed” section), 40437 (Table 2) and 40440 (Table 3). Also, the ATCC number of A. viscosus was incorrectly given as 29522 throughout the published article and should be correctly shown as 15987 in the following places: p. 40429 (“Bacterial strains and culture conditions” section and “Minimum inhibitory concentration determination” section), p. 40430 (“Determination of antibiofilm activity using tissue culture plate assay (TCP)” section), p. 40434 (“Antimicrobial assay of quantum curcumin against clinical isolates of Porphyromonas gingivalis and select reference strains” section and “Determination of minimum inhibitory concentration” section), p. 40435 (“Growth rate analysis” section), p. 40437 (Table 2), and on p. 40438 (caption to Fig. 7 (twice), caption to Fig. 8, and sixth line of “Discussion” section). An error was also present in the published article in the co-author name spelling for K. Sharma. The correct spelling of the author names is as shown here. The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers. © The Royal Society of Chemistry.
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy
(Multidisciplinary Digital Publishing Institute (MDPI), 2024) Komal Kumari; Amarnath Singh; Archana Chaudhary; Rakesh Kumar Singh; Asheesh Shanker; Vinay Kumar; Rizwanul Haque
Immunotherapies can treat many cancers, including difficult-to-treat cases such as lung cancer. Due to its tolerability, long-lasting therapeutic responses, and efficacy in a wide spectrum of patients, immunotherapy can also help to treat lung cancer, which has few treatment choices. Tumor-specific antigens (TSAs) for cancer vaccinations and T-cell therapies are difficult to discover. Neoantigens (NeoAgs) from genetic mutations, irregular RNA splicing, protein changes, or viral genetic sequences in tumor cells provide a solution. NeoAgs, unlike TSAs, are non-self and can cause an immunological response. Next-generation sequencing (NGS) and bioinformatics can swiftly detect and forecast tumor-specific NeoAgs. Highly immunogenic NeoAgs provide personalized or generalized cancer immunotherapies. Dendritic cells (DCs), which originate and regulate T-cell responses, are widely studied potential immunotherapeutic therapies for lung cancer and other cancers. DC vaccines are stable, reliable, and safe in clinical trials. The purpose of this article is to evaluate the current status, limitations, and prospective clinical applications of DC vaccines, as well as the identification and selection of major histocompatibility complex (MHC) class I and II genes for NeoAgs. Our goal is to explain DC biology and activate DC manipulation to help researchers create extremely potent cancer vaccines for patients. © 2024 by the authors.
Quantum curcumin mediated inhibition of gingipains and mixed-biofilm of Porphyromonas gingivalis causing chronic periodontitis
(Royal Society of Chemistry, 2018) Ashish Kumar Singh; Shivangi Yadav; Kavanjali Sharma; Zeba Firdaus; Prerana Aditi; Kaushik Neogi; Monika Bansal; Munesh Kumar Gupta; Asheesh Shanker; Rakesh Kumar Singh; Pradyot Prakash
Periodontitis is a biofilm-associated irreversible inflammation of the periodontal tissues. Reports suggest the role of Porphyromonas gingivalis specific Arg- and Lys-specific proteinases in the orchestration of the initiation and progression of periodontal diseases. These proteinases are precisely termed as gingipains R and K. Curcumin is an active polyphenol that is extracted from the rhizomes of Curcuma longa. However, the molecule curcumin owing to its high hydropathy index and poor stability has not been able to justify its role as frontline drug modality in the treatment of infectious and non-infectious diseases as claimed by several investigators. In the present study, at first, we synthesized and characterized quantum curcumin, and investigated its biocompatibility. This was subsequently followed by the evaluation of the role of quantum curcumin as an antimicrobial, anti-gingipains and antibiofilm agent against Porphyromonas gingivalis and select reference strains. We have successfully synthesized the quantum curcumin utilizing a top-down approach with the average size of 3.5 nm. Apart from its potent antimicrobial as well as antibiofilm properties, it also significantly inhibited the gingipains in a dose-dependent manner. At the minimal concentration of 17.826 μM, inhibition up to 98.7% and 89.4% was noted for gingipain R and K respectively. The data was also supported by the in silico docking experiments which revealed high exothermic enthalpies (−7.01 and −7.02 cal mol−1). Besides, the inhibition constant was found to be 7.24 μM and 7.1 μM against gingipains R and K respectively. The results suggest that quantum curcumin is a potential drug candidate which needs further clinical validation. © The Royal Society of Chemistry.